Business Wire

VA-DXC-TECHNOLOGY

25.2.2020 15:02:10 CET | Business Wire | Press release

Share
DXC Technology Advances Deployments of Augmented, Virtual and Mixed Reality Technologies for Enterprises in the Connected, Digital Workplace

DXC Technology (NYSE: DXC) today highlighted how it is helping enterprises accelerate the adoption of augmented reality (AR), virtual reality (VR) and mixed reality (MR) technologies to support immersive experiences in ways that can significantly improve productivity, quality and efficiency.

According to Gartner, by 2022, 70% of enterprises will be experimenting with immersive technologies for consumer and enterprise use, and 25% will have deployed them to production.* DXC is using AR, VR and MR technologies today to transform the future of work, and the company is seeing widespread implementation to improve safety, connect remote workers, assist with complex tasks and enhance training and collaboration – all in ways that drive business results and profitability.

“Digital transformation in the workplace is edging towards an inflection point as enterprises are incorporating immersive solutions that connect the real world with the virtual world,” said Maria Pardee, DXC’s senior vice president and general manager, Workplace and Mobility. “DXC is using the power of AR, VR and MR to align the next-generation digital capabilities employees want so they can be more mobile and independent, with the critical security, production prowess and agility that today’s businesses demand.”

DXC Deploys Mixed Reality Employee Training at Water Treatment Leader Ixom

A market leader in water treatment and chemical distribution in Australia and New Zealand, Ixom turned to DXC to develop a custom training and assessment application using mixed reality on Microsoft HoloLens.

In the past, Ixom training and learning assessments were conducted at customer sites, requiring travel, scheduling and employee resources to mitigate safety risks. Now, using DXC’s mixed reality application for Microsoft HoloLens — custom built for Ixom — employees can participate in the required training and learning assessment at any Ixom office or remote location. The resulting increase in flexibility, autonomy and mobility has reduced Ixom travel costs, minimized employee safety risks and essentially eliminated the potential for exposure to hazardous materials during training at treatment facilities.

DXC is named a Leader in Advanced Digital Workplace Services Overall in the NelsonHall Evaluation & Assessment Tool (NEAT) Report 2019 . DXC is also an official partner in the Microsoft HoloLens Mixed Reality Partner Program, a status that reflects the company’s commitment to designing, developing and deploying solutions that help customers accelerate their digital transformations using mixed reality technologies.

The following DXC offerings enable immersive solutions using AR/VR technologies:

  • DXC AR/VR services consist of AR/VR consulting, custom application development and system integration for a range of AR/VR devices including Microsoft HoloLens. DXC is also a Distributor Managed Partner for HoloLens 2 and provides services for MR business applications such as Microsoft Dynamics 365 Guides.
  • DXC Remote Expert is an innovative AR solution that enables field workers in various industries (automotive, energy and utilities, manufacturing, travel and transportation, and healthcare) to display work instructions via a hands-free interface on their wearable or mobile devices and connect to experts at other locations when they need guidance.
  • DXC Unified Endpoint Management enables enterprises to manage and secure mobile, PC, internet-of-things (IoT) and wearable devices in a single pane of glass. DXC’s collaboration with industry-leading technology partners, combined with DXC transformation, delivery and support services, provides users with secure and seamless access to enterprise applications, data and services independent of operating system, device type or location.
  • DXC Workplace IoT enables enterprises to securely deploy and manage smart connected devices by combining IoT solutions, best practices, and market-leading platforms and technology partners to improve production, operational and human outcomes; automate processes with analytics; and gain situational awareness.
  • DXC Open Health Connect creates a connected ecosystem that optimizes services for patients, healthcare providers and payers, using AR to provide better patient outcomes.

*Smarter With Gartner, Top 10 Strategic Technology Trends for 2019, October 2019, https://www.gartner.com/smarterwithgartner/gartner-top-10-strategic-technology-trends-for-2019 .

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye